BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 1143006)

  • 1. 3-O-methyldopa uptake and inhibition of L-dopa at the blood-brain barrier.
    Wade LA; Katzman R
    Life Sci; 1975 Jul; 17(1):131-6. PubMed ID: 1143006
    [No Abstract]   [Full Text] [Related]  

  • 2. Regional distribution of catecholamines in rat brain after L-3-O-methyldopa and L-dopa.
    Bartholini G; Lloyd KG; Pletscher A
    Life Sci; 1974 Jan; 14(2):323-8. PubMed ID: 4813592
    [No Abstract]   [Full Text] [Related]  

  • 3. Synthetic amino acids and the nature of L-DOPA transport at the blood-brain barrier.
    Wade LA; Katzman R
    J Neurochem; 1975 Dec; 25(6):837-42. PubMed ID: 1206400
    [No Abstract]   [Full Text] [Related]  

  • 4. Catechol-O-methyltransferase and Parkinson's disease.
    Reches A; Fahn S
    Adv Neurol; 1984; 40():171-9. PubMed ID: 6695593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 3-O-Methyldopa inhibits astrocyte-mediated dopaminergic neuroprotective effects of L-DOPA.
    Asanuma M; Miyazaki I
    BMC Neurosci; 2016 Jul; 17(1):52. PubMed ID: 27456338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemical lonization mass spectrometric measurement of alpha-methyldopa and s-dopa metabolites in rat brain regions.
    Freed CR; Weinkam RJ; Melmon KL; Castagnoli N
    Anal Biochem; 1977 Apr; 78(2):319-32. PubMed ID: 851208
    [No Abstract]   [Full Text] [Related]  

  • 7. Brain tissue and plasma assay of L-DOPA and alpha-methyldopa metabolites by high performance liquid chromatography with electrochemical detection.
    Freed CR; Asmus PA
    J Neurochem; 1979 Jan; 32(1):163-8. PubMed ID: 759567
    [No Abstract]   [Full Text] [Related]  

  • 8. The neurochemistry of Parkinson's disease: effect of L-dopa therapy.
    Lloyd KG; Davidson L; Hornykiewicz O
    J Pharmacol Exp Ther; 1975 Dec; 195(3):453-64. PubMed ID: 489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 3-O-methyldopa blocks dopa metabolism in rat corpus striatum.
    Reches A; Fahn S
    Ann Neurol; 1982 Sep; 12(3):267-71. PubMed ID: 7137962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. L-dopa in Parkinsonism. A possible mechanism of action.
    Ng LK; Chase TN; Colburn RW; Kopin IJ
    Neurology; 1972 Jul; 22(7):688-96. PubMed ID: 4673250
    [No Abstract]   [Full Text] [Related]  

  • 11. Effects of histidine on the transport of L-dopa by slices of brain cortex and striatum of the rat.
    Herreros B; Garcia-Sancho J; Barbosa E
    J Neurochem; 1978 May; 30(5):1101-4. PubMed ID: 660187
    [No Abstract]   [Full Text] [Related]  

  • 12. Absorption, metabolism and distribution of (14C)-O-methyldopa and (14C)-L-dopa after oral administration to rats.
    Rivera-Calimlim L
    Br J Pharmacol; 1974 Feb; 50(2):259-63. PubMed ID: 4425764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transport of L-proline by rat brain slices.
    Balcar VJ; Johnston GA; Stephanson AL
    Brain Res; 1976 Jan; 102(1):143-51. PubMed ID: 1247876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brain DOPA-5-HTP decarboxylase activity after the chronic administration of L-dopa or 5-hydroxy-L-tryptophan in normal and lesioned cats.
    Roberge AG; Poirier LJ
    Brain Res; 1974 Aug; 76(3):401-12. PubMed ID: 4546739
    [No Abstract]   [Full Text] [Related]  

  • 15. Polyamine turnover in different regions of rat brain.
    Shaskan EG; Snyder SH
    J Neurochem; 1973 May; 20(5):1453-60. PubMed ID: 4716837
    [No Abstract]   [Full Text] [Related]  

  • 16. The uptake of -( 3 H)aminobutyric acid by slices from various regions of rat brain and the effect of lithium.
    Bond PA
    J Neurochem; 1973 Feb; 20(2):511-7. PubMed ID: 4698296
    [No Abstract]   [Full Text] [Related]  

  • 17. Enhancement by 6-hydroxydopamine of the effects of DOPA upon the motor activity of rats.
    Schoenfeld RI; Uretsky NJ
    J Pharmacol Exp Ther; 1973 Sep; 186(3):616-24. PubMed ID: 4728340
    [No Abstract]   [Full Text] [Related]  

  • 18. 3-O-methyldopa and the response to levodopa in Parkinson's disease.
    Nutt JG; Woodward WR; Gancher ST; Merrick D
    Ann Neurol; 1987 Jun; 21(6):584-8. PubMed ID: 3606046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Levodopa and 3-OMD levels in Parkinson patients treated with Duodopa.
    Antonini A; Bondiolotti G; Natuzzi F; Bareggi SR
    Eur Neuropsychopharmacol; 2010 Oct; 20(10):683-7. PubMed ID: 20570113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High affinity uptake of cyclic AMP in rat brain slices.
    Johnston GA; Balcar VJ
    Brain Res; 1973 Sep; 59():451-53. PubMed ID: 4355890
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.